Diabetes:concerns about long-term use of GLP-1 analogues. Holmes D. Nat Rev Endocrinol . 2016Holmes D. Diabetes: concerns about long-term use of GLP-1 ana- logues. Nat Rev Endocrinol 2016;12:186.Holmes D. Diabetes: concerns about long-term use of GLP-1 analogues[J]. Nat Rev ...
The use of long-acting GLP-1 receptor agonist for 优质文献 相似文献Long-term effectiveness and safety of liraglutide in clinical practice. Aim: The rising adoption of liraglutide in clinical practice calls for an update on its long-term effectiveness and safety. The aims of this paper were to...
Based on such qualities, however, there is little reason to worry about the prolonged use of GLP1 analogs in patients with diabetes mellitus and COVID-19, since during COVID-19, persons with cardiovascular or kidney diseases had worse outcomes than those who did not have these conditions. ...
Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational studyGLP-1 receptor agonistglycaemic controlobservational studyAims To evaluate in a real﹚orld setting the effectiveness and tolerability of available GLPRA drugs in patients with type 2 diabetes after a ...
Changes in body weight, adherence, and appetite during 2 years of calorie restriction: the CALERIE 2 randomized clinical trial Article 06 March 2020 Six-month changes in ghrelin and glucagon-like peptide-1 with weight loss are unrelated to long-term weight regain in obese older adults Artic...
From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy Promoting long-term adherence to lifestyle modification and choice of antidiabetic agent with low hypoglycemia risk profile and positive weight profile cou... I Dicembrini,L Pala,CM Rotella - 《...
Studies of medications approved for other purposes but tested for obesity treatment were also reviewed. Findings Obesity medications approved for long-term use, when prescribed with lifestyle interventions, produce additional weight loss relative to placebo ranging from approximately 3% of initial weight ...
Previous studies, using clinical trial data, demonstrated that once-weekly (OW) semaglutide is dominant versus other glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in China. This study aims to evaluate the long-term clinical and economic effects of switching to OW semaglutide from other ...
We have recently shown that the addition of Liraglutide to insulin in the treatment of well controlled, non-obese patients with type 1 diabetes leads to a significant further rapid reduction in glycemia, glycemic excursions, HbA1c, insulin requirements and body weight within days. We now present ...
Recently, there has been an increased use of semaglutide drugs, which primarily function as glucagon-like peptide 1 (GLP-1) agonists. These drugs stimulate insulin release and reduce glucagon secretion, helping to control blood sugar levels. Further, anti-diabetic ...